RTP Mobile Logo
Recent Advances and Real-World Implications in Medical Oncology: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology Network (Webinar Video Proceedings)
Released August 2022

Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O’Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinivas. Published August 25, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer, genitourinary cancers, multiple myeloma, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers and lung cancer.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, lung and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing clinical trials in breast, gastrointestinal, genitourinary, lung and select hematologic cancers, and refer appropriate patients for participation.
    • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in individualizing the care of patients with cancer.
    • Educate patients with hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer treatment algorithms, considering new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 7 (audio) and 6.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AON22/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/AON22/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AON22/Video/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/AON22.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Neeraj Agarwal, MD
    Professor of Medicine
    Senior Director for Clinical Research Innovation
    Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
    Director, Center of Investigational Therapeutics
    Director, Genitourinary Oncology Program
    Huntsman Cancer Institute, University of Utah (NCI-CCC)
    Salt Lake City, Utah

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Nektar, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc, TRACON Pharmaceuticals Inc.

    Harold J Burstein, MD, PhD
    Institute Physician, Dana-Farber Cancer Institute
    Professor of Medicine, Harvard Medical School
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Ibiayi Dagogo-Jack, MD
    Assistant Professor of Medicine
    Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, BostonGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novocure Inc, Pfizer Inc, Sanofi Genzyme, Syros Pharmaceuticals Inc, Xcovery; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc.

    Rafael Fonseca, MD
    Chief Innovation Officer
    Getz Family Professor of Cancer
    Distinguished Mayo Investigator
    Mayo Clinic in Arizona
    Phoenix, Arizona

    Consulting Agreements: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, H3 Biomedicine, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Merck, Novartis, Oncopeptides, ONCOtracker, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Scientific Advisory Board: Adaptive Biotechnologies Corporation, Caris Life Sciences, OncoMyx Therapeutics, ONCOtracker.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    Director, Lymphoma Program
    Siteman Cancer Center
    St Louis, Missouri

    Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc.

    Rutika Mehta, MD, MPH
    Assistant Member in the Department of Gastrointestinal Oncology
    Moffitt Cancer Center
    Assistant Professor in the Department of Oncologic Sciences
    University of South Florida
    Tampa, Florida

    Advisory Committee: Astellas, Bristol-Myers Squibb Company, Lilly; Consulting Agreement: Lilly; Speakers Bureau: Daiichi Sankyo Inc, Natera Inc.

    Craig Moskowitz, MD
    Physician in Chief and Interim Deputy Cancer Center Director
    Sylvester Comprehensive Cancer Center
    Professor of Medicine, Miller School of Medicine
    University of Miami Health System
    Miami, Florida

    Research Funding: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Merck, Seagen Inc; Scientific Advisory Board: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Merck, Molecular Templates, Seagen Inc, Takeda Pharmaceuticals USA Inc.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Pfizer Inc, Seagen Inc.

    Krina Patel, MD, MSc
    Associate Professor
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Arcellx, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Curio Bioscience, Janssen Biotech Inc, Karyopharm Therapeutics, Legend Biotech, Merck, Pfizer Inc; Contracted Research: Allogene Therapeutics, Nektar.

    Philip A Philip, MD, PhD, FRCP
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Henry Ford Cancer Institute
    Wayne State University
    Detroit, Michigan

    No relevant conflicts of interest to disclose.

    Suresh S Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Roberto C Goizueta Chair for Cancer Research
    Executive Director, Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genmab, GlaxoSmithKline, Lilly, Merck, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genmab, GlaxoSmithKline, Merck, Takeda Pharmaceuticals USA Inc; Contracted Research (to Institution): Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genmab, GlaxoSmithKline, Merck, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc.

    Sandy Srinivas, MD
    Professor of Oncology
    Clinical Research Leader, GU Oncology
    Stanford University
    Stanford, California

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Novartis; Contracted Research: Bayer HealthCare Pharmaceuticals, Merck, Novartis; Data and Safety Monitoring Board/Committee: Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by an educational grant from AbbVie Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Lilly, Merck, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Puma Biotechnology Inc, Seagen Inc, and Taiho Oncology Inc.

    Release date: August 2022
    Expiration date: August 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):